Patents by Inventor Chuanhao HUANG

Chuanhao HUANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240116952
    Abstract: The disclosure relates to KRASG12D inhibitor compounds having the structure of Formula (A) or Formula (B), pharmaceutical compositions thereof, and methods of use thereof for inhibiting, treating, and/or preventing KRASG12D mutation-associated diseases, disorders and conditions.
    Type: Application
    Filed: September 8, 2023
    Publication date: April 11, 2024
    Inventors: Jiasheng LU, Xiang JI, Xianchao DU, Yanpeng WU, Xiaolin HE, Guangwei REN, Lina CHU, Chuanhao HUANG, Xingwu ZHU, Yuhua ZHANG, Jian GE, Tianlun ZHOU, Xiangsheng YE, Xianqi KONG, Dawei CHEN
  • Publication number: 20240059712
    Abstract: The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of the KRAS-G12D protein in a cell and are thus useful for treating, inhibiting, and preventing KRAS-G12D-associated diseases, disorders and conditions, including cancers.
    Type: Application
    Filed: September 13, 2023
    Publication date: February 22, 2024
    Inventors: Jiasheng LV, Xiang JI, Gang WU, Bin ZONG, Qiguo ZHANG, Yanpeng WU, Xiangyang LI, Yuhui CHEN, Yongyue CHEN, Chuanhao HUANG, Xingwu ZHU, Xiaolin HE, Yao LIU, Yuhua ZHANG, Jian GE, Tianlun ZHOU, Xiangsheng YE, Xianqi KONG, Dawei CHEN
  • Publication number: 20240024346
    Abstract: CD73 (also known as ecto-5?-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I? and pharmaceutically acceptable esters or salts thereof.
    Type: Application
    Filed: November 25, 2021
    Publication date: January 25, 2024
    Inventors: Jiasheng LU, Gang CHEN, Qiguo ZHANG, Xianqi KONG, Dawei CHEN, Chuanhao HUANG, Xingwu ZHU, Yuhua ZHANG
  • Publication number: 20230321253
    Abstract: The disclosure relates to bifunctional KRAS-G12D-modulating compounds having the structure W-L-T, where W is a targeting group that binds specifically to KRAS-G12D protein, T is an E3-ligase binding group, and L is absent or is a bivalent linking group that connects W and T together via a covalent linkage. Compounds and pharmaceutical compositions thereof can promote degradation of the KRAS-G12D protein in a cell and are thus useful for treating, inhibiting, and preventing KRAS-G12D-associated diseases, disorders and conditions, including cancers.
    Type: Application
    Filed: March 9, 2023
    Publication date: October 12, 2023
    Inventors: Jiasheng LV, Xiangyang LI, Xiang JI, Yuhui CHEN, Yongyue CHEN, Chuanhao HUANG, Xingwu ZHU, Xiaolin HE, Jian GE, Tianlun ZHOU, Xianqi KONG, Dawei CHEN, Xiangsheng YE
  • Publication number: 20230295213
    Abstract: CD73 (also known as ecto-5?-nucleotidase) inhibitor compounds are provided, as well as compositions and uses thereof for treating or preventing CD73-associated or related diseases, disorders and conditions, including cancer- and immune-related disorders. CD73 inhibitor compounds include compounds having the structure set forth in Formula I? and pharmaceutically acceptable esters or salts thereof.
    Type: Application
    Filed: November 24, 2022
    Publication date: September 21, 2023
    Inventors: Jiasheng LU, Gang CHEN, Qiguo ZHANG, Xianqi KONG, Dawei CHEN, Chuanhao HUANG, Xingwu ZHU, Yuhua ZHANG